1. Oncology
CHU CD137 agonist switch antibody
solid tumors
Description/Summary:
- Managed By:
-
3. Chugai
- Roche Only
1. Oncology
CHU codrituzumab
Hepatocellular carcinoma
Description/Summary:
- Managed By:
-
3. Chugai
- Partner:
- Chugai
1. Oncology
CHU SPYK04
solid tumors
Description/Summary:
SPYK04 is a small molecule drug developed in-house by Chugai
- Managed By:
-
3. Chugai
- Roche Only
1. Oncology
CHU LUNA18
solid tumors
Description/Summary:
LUNA18 is an oral cyclic peptide RAS inhibitor, and a Phase I clinical trial has been initiated for solid
tumors by Chugai
- Managed By:
-
3. Chugai
- Roche Only
1. Oncology
RG6007 HLA-A2-WT1 X CD3
Adult acute myeloid leukemia
Description/Summary:
RG6007 (HLA-A2-WT1 x CD3) is a T cell receptor (TCR)-like T-cell bispecific antibody targeting the
HLA-A2-WT1 complex on tumor cells and CD3 on T-cells.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6026 Glofitamab
relapsed or refractory non-Hodgkin's lymphoma
Description/Summary:
Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to
engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody
activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as
non-Hodgkin’s lymphoma. A phase I clinical trial is evaluating RG6026 for the treatment of relapsed or
refractory non-Hodgkin's lymphoma.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6058 tiragolumab
Heme and solid tumors combinations
Description/Summary:
tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and
prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein
(TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor. A phase I
clinical trial is evaluating tiragolumab in combination with Tecentriq for the treatment of solid tumors.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6076 CD19-4-1BBL
heme tumours
Description/Summary:
CD19-4-1BBL(RG6076) is a fusion protein targeting the 4-1BB ligand to cells bearing CD19 acting as an NK-
and T-cell co-stimulator.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6129 HLA-A2-MAGE-A4 X CD3
solid tumors
Description/Summary:
Bispecific Antibody targeting HLA-A2 restricted Mage-A4 epitope and CD3
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6156 EGFRvIII X CD3
glioblastoma
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6160 cevostamab
relapsed or refractory multiple myeloma
Description/Summary:
cevostamab (FcRH5 X CD3)
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
1. Oncology
RG6171 giredestrant
ER-positive and HER2-negative metastatic breast cancer
Description/Summary:
RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the
estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may
be able to change the shape of the receptor in such a way that the cell eliminates it by degradation. A
phase I clinical trial is evaluating RG6171 for the treatment of ER-positive and HER2-negative metastatic
breast cancer.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6180 autogene cevumeran
solid tumors
2025+
Description/Summary:
autogene cevumeran (Individualized Neoantigen-Specific Therapy, iNeST (RG6180) is a messenger RNA
(mRNA)-based, individually tailored, personalized cancer vaccine. Each vaccine will be made using unique
neoantigen signatures from an individual patient’s tumor, which is expected to elicit an effective immune
response against that patient’s tumor. A phase I clinical trial is evaluating iNeST for the treatment of
solid tumors.
- Managed By:
-
4. Genentech Research and Early Development
- Partner:
- BioNTech AG
1. Oncology
RG6185 belvarafenib
solid tumors
Description/Summary:
belvarafenib (RG6185, GDC-5573, HM95573) is a selective small-molecule inhibitor of the RAF family
kinases designed to inhibit the MAPK pathway, which is frequently activated in human tumors and drives
tumor growth. A phase I clinical trial is evaluating RG6185 for the treatment of solid tumors.
- Managed By:
-
4. Genentech Research and Early Development
- Partner:
- Hanmi Pharmaceutical
1. Oncology
RG6189 FAP-CD40
Solid tumors
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6194 runimotamab
metastatic HER2-positive cancers
Description/Summary:
runimotamab (HER2 X CD3) is a bispecific antibody designed to target both the HER2-positive cells and CD3
on T cells. This dual-targeting antibody is designed to induce a polyclonal T-cell response against
HER2-positive tumors. A phase I clinical trial is evaluating RG6194 for the treatment of metastatic
HER2-positive cancers.
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
1. Oncology
RG6234
multiple myeloma
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6279 PD1-IL2v
Solid tumours
Description/Summary:
The immunocytokine PD1-IL2v is an antibody fusion protein blocking PD1 combined with an engineered
interleukin-2 variant (IL2v) inducing immune-modulating activity
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6286
Locally advanced or metastatic colorectal cancer
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
1. Oncology
RG6290 MAGE-A4 ImmTAC
solid tumors
Description/Summary:
The trial (NCT03973333) is designed to study the safety and preliminary activity of MAGE-A4 ImmTAC as a
monotherapy and in combination with atezolizumab (Tecentriq) in patients with MAGE-A4-expressing cancers.
- Managed By:
-
4. Genentech Research and Early Development
- Partner:
- Immunocore
1. Oncology
RG6292 Anti-CD25
solid tumors
Description/Summary:
RG6292 is a monoclonal antibody that targets CD25 (IL-2Rα). The antibody mediates the depletion of
regulatory T-cells (Tregs), a major suppressor of the anti-cancer immune response. RG6292 does not
interfere with IL-2 signaling of other immune cells which are acting against the tumor. Phase I clinical
trials in solid tumors are evaluating RG6292 as monotherapy (NCT 04158583) and in combination with
atezolizumab (NCT04642365).
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6323 IL15/IL15Ra-Fc
solid tumours
Description/Summary:
IL15/IL15Ra-Fc alone, and in combination with Tecentriq
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
1. Oncology
RG6330 KRAS G12C
metastatic solid tumors with KRAS G12C mutation
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
1. Oncology
RG6333 CD19 X CD28
relapsed or refractory Non Hodgkin's Lymphoma
Description/Summary:
CD19 X CD28 in combination with glofitimab
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6344 BRAF inhibitor (3)
solid tumors
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6392
Oncology
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
1. Oncology
RG6433 SHP2i
Solid tumors
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
1. Oncology
RG6440 TGF-beta (SOF10)
Solid tumors
Description/Summary:
Phase I study in solid tumors of RG6440 an Anti-TGF-beta monoclonal antibody
- Managed By:
-
3. Chugai
- Roche Only
1. Oncology
RG7440 Ipatasertib
prostate cancer previously treated with androgen receptor-targeted therapy
Description/Summary:
Ipatasertib plus Tecentriq is being tested in a Phase I study in prostate cancer patients who have been
previously treated with androgen receptor-targeted therapy
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7440 ipatasertib
metastatic castration-resistant prostate cancer and solid tumors in combination
with rucaparib
Description/Summary:
Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell
growth and survival. A phase I clinical trial is evaluating ipatasertib with rucaparib (a small-molecule
PARP inhibitor) for the treatment of metastatic castration-resistant prostate cancer and solid tumors.
- Managed By:
-
1. Roche Group
- Partner:
- Array BioPharma (ipatasertib), Clovis Oncology (rucaparib)
1. Oncology
RG7446 atezolizumab
Tecentriq
Solid tumors (MORPHEUS platform)
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab) is a
monoclonal antibody that targets PD-L1 (programmed death ligand 1) aiming to prevent cancer immune
evasion. MORPHEUS pancreatic cancer study is testing a number of cancer immunotherapy combinations to
inform future development. MORPHEUS is a phase Ib/II adaptive development platform established by Roche to
assess the efficacy and safety of combination cancer immunotherapies.
- Managed By:
-
1. Roche Group
- Partner:
- Cotellic in collaboration with Exelixis, BL-8040 in collaboration with BioLineRX,
PEGPH20 in collaboration with Halozyme
1. Oncology
RG7601 venetoclax
Venclexta/Venclyxto
relapsed or refractory myelodysplastic syndromes in combination with azacitidine
Description/Summary:
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore
apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family
protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role
in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and
resistance. A phase I clinical trial is evaluating Venclexta as a single agent and in combination with the
hypomethylating agent azacitidine in patients with relapsed or refractory myelodysplastic syndromes.
- Managed By:
-
1. Roche Group
- Partner:
- AbbVie, Walter and Eliza Hall Institute
1. Oncology
RG7802 cibisatamab
solid tumors
Description/Summary:
cibisatamab (RG7802) is a bispecific antibody designed to simultaneously target carcinoembryonic antigen
(CEA) expressed on tumor cells and the CD3 receptor present on T cells, triggering T cell activation,
migration and tumor killing. A phase I clinical trial is evaluating cibisatamab for the treatment of
CEA-expressing solid tumors, as a single agent and in combination with atezolizumab.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7827 FAP 4-1BBL
solid tumors
Description/Summary:
RG7827 (FAP 4-1BBL FP) is an agonistic immune modulator and targeted T-cell co-stimulator, which inhibits
tumor growth by activating tumor-specific T-cells. RG7827 has an antibody-like structure, with one arm
binding to FAP, which is a protein found in the stroma of many solid tumor types, and the other arm
carrying the signaling molecule, 4-1BBL. A phase I clinical trial is evaluating RG7827 for the treatment
of solid tumors.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG7828 mosunetuzumab
hematologic tumors
Description/Summary:
mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody
designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to
redirect T cells to attack cancer cells. A phase I clinical trial is evaluating mosunetuzumab for the
treatment of hematologic tumors.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
SQZ PBMC Vaccine
solid tumours
Description/Summary:
SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6026 Glofitamab
1L ctDNA higher risk Diffuse Large B-Cell Lymphoma
2025+
Description/Summary:
Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to
engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody
activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as
non-Hodgkin’s lymphoma.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6058 tiragolumab
1L recurrent/metastatic PD-L1 positive squamous cell head and neck carcinoma
2025+
Description/Summary:
Randomised Phase II (SKYSCRAPER-09) 1L recurrent/metastatic PD-L1 positive squamous cell head and neck
carcinoma in combination with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal
antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell
immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel
immune inhibitory receptor.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6058 tiragolumab
cervical cancer in combination with tecentriq
2025+
Description/Summary:
Randomised Phase II (SKYSCRAPER-04) in metastatic and/or recurrent PD-L1+ cervical cancer in combination
with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to
TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain
protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6058 tiragolumab
1L non-squamous non-small cell lung cancer (NSCLC) in combination with tecentriq
2025+
Description/Summary:
Randomised Phase II/III in 1L non-squamous non-small cell lung cancer (NSCLC) in combination with
Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT
and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein
(TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6058-10 tiragolumab
neoadjuvant and adjuvant non-squamous non-small cell lung cancer (NSCLC) in
combination with Tecentriq
2025+
Description/Summary:
Randomised Phase II in neoadjuvant and adjuvant non-squamous non-small cell lung cancer (NSCLC) in
combination with Tecentriq. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed
to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and
ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory
receptor.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6107 crovalimab
sickle cell disease
2025+
Description/Summary:
Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using
recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit
complement activation, which is the cause of a number of diseases. As the complement system is a key
innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of
complement-mediated diseases.
- Managed By:
-
1. Roche Group
- Partner:
- Chugai
1. Oncology
RG6139 Anti-PD1 x LAG3
solid tumors
Description/Summary:
The bispecific monoclonal antibody PD1 x LAG3 (RG6139) binds to the PD-1 and LAG-3 inhibitory checkpoint
receptors on the surface of T-cells. PD1 x LAG3 MAb enable preferential targeting of dysfunctional
effector T-cells over regulatory T-cells mediating immunosuppressive effects while restoring anti-tumor
immune response. RG6139 is currently in phase I clinical study for solid tumors.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
1. Oncology
RG6171 giredestrant
neoadjuvant ER+ breast cancer
2025+
Description/Summary:
RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the
estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may
be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6171 giredestrant
ER-positive and HER2-negative 2/3L metastatic breast cancer
2022
Description/Summary:
RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the
estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may
be able to change the shape of the receptor in such a way that the cell eliminates it by degradation. A
phase II clinical trial is evaluating RG6171 for the treatment of ER-positive and HER2-negative 2/3L
metastatic breast cancer.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6180 autogene cevumeran
first line melanoma
2025+
Description/Summary:
autogene cevumeran (Individualised Neoantigen-Specific Therapy, iNeST (RG6180) is a messenger RNA
(mRNA)-based, individually tailored, personalized cancer vaccine. Each vaccine will be made using unique
neoantigen signatures from an individual patient’s tumor, which is expected to elicit an effective immune
response against that patient’s tumor. A phase II clinical trial is evaluating iNeST for the treatment of
first line melanoma.
- Managed By:
-
4. Genentech Research and Early Development
- Partner:
- BioNTech AG
1. Oncology
RG6416 bepranemab
Alzheimer's disease
Description/Summary:
A Phase II Study to evaluate the efficacy, safety, and tolerability of Bepranemab (UCB0107) in study
participants with prodromal to mild Alzheimer’s Disease (AD)
- Managed By:
-
0. -
- Partner:
- UCB
1. Oncology
RG7601 venetoclax
Venclexta/Venclyxto
relapsed or refractory multiple myeloma
Description/Summary:
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore
apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family
protein. A phase II clinical trial is evaluating Venclexta in combination with the carfilzomib and
dexamethasone for the treatment of patients with relapsed or refractory acute myeloid leukemia.
- Managed By:
-
1. Roche Group
- Partner:
- AbbVie, Walter and Eliza Hall Institute
1. Oncology
RG3502 trastuzumab emtansine
Kadcyla
2L+ HER-2 positive PD-L1 positive mBC in combination with Tecentriq
Description/Summary:
Trastuzumab emtansine (T–DM1) is a novel antibody–drug conjugate that combines the therapeutic effect of
trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent
chemotherapy agent, to specifically target HER2-positive tumors.
- Managed By:
-
1. Roche Group
- Partner:
- ImmunoGen
1. Oncology
RG3502-10 trastuzumab emtansine
Kadcyla
high risk patients with adjuvant HER2-positive breast cancer in combination with
Tecentriq
2025+
Description/Summary:
Kadcyla (trastuzumab emtansine) is a novel antibody-drug conjugate that combines the therapeutic effect
of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent
chemotherapy agent, to specifically target HER2-positive tumors.
- Managed By:
-
1. Roche Group
- Partner:
- ImmunoGen
1. Oncology
RG6026 Glofitamab
2L+ SCT-ineligible Diffuse Large B-Cell Lymphoma
2025+
Description/Summary:
Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to
engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody
activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as
non-Hodgkin’s lymphoma.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6058 tiragolumab
1L non-small cell lung cancer (NSCLC) in combination with Tecentriq
2022
Description/Summary:
Randomised Phase III (SKYSCRAPER-01) of tiragolumab plus Tecentriq in 1L non-small cell lung cancer
(NSCLC) patients whose tumours express PD-L1 (TPS>50%). tiragolumab (anti-TIGIT, RG6058) is a fully human
monoclonal antibody designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR).
T cell immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a
novel immune inhibitory receptor.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6058 tiragolumab
stage III unresectable 1L non-small cell lung cancer (NSCLC) in combination with
Tecentriq
2024
Description/Summary:
Randomised Phase III (SKYSCRAPER-03) of tiragolumab plus Tecentriq in stage III unresectable 1L non-small
cell lung cancer (NSCLC) patients. tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody
designed to bind to TIGIT and prevent its interaction with poliovirus receptor (PVR). T cell
immunoglobulin and ITIM domain protein (TIGIT), a member of the immunoglobulin superfamily, is a novel
immune inhibitory receptor.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6058 tiragolumab
locally advanced esophageal cancer
2025+
Description/Summary:
Randomised Phase III (SKYSCRAPER-07) of tiragolumab plus Tecentriq in locally advanced esophageal cancer.
tiragolumab (anti-TIGIT, RG6058) is a fully human monoclonal antibody designed to bind to TIGIT and
prevent its interaction with poliovirus receptor (PVR). T cell immunoglobulin and ITIM domain protein
(TIGIT), a member of the immunoglobulin superfamily, is a novel immune inhibitory receptor.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6107 crovalimab
Atypical Hemolytic Uremic Syndrome
2024
Description/Summary:
Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using
recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit
complement activation, which is the cause of a number of diseases. As the complement system is a key
innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of
complement-mediated diseases.
- Managed By:
-
1. Roche Group
- Partner:
- Chugai
1. Oncology
RG6114 Inavolisib
metastatic ER-positive and HER2-negative breast cancer
2024
Description/Summary:
Inavolisib (RG6114, GDC-0077) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K
signaling is implicated in a broad range of human cancers, and activating mutations in the PI3K
alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth
and survival.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6171 giredestrant
adjuvant ER+ breast cancer
2025+
Description/Summary:
RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the
estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may
be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG6171 giredestrant
metastatic ER+ breast cancer
2025+
Description/Summary:
RG6171 (GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the
estrogen receptor to limit its function. In addition, when SERDs bind to the estrogen receptor, they may
be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7440 ipatasertib
first line castration-resistant prostate cancer
2022
Description/Summary:
Ipatasertib (RG7440) is a small molecule pan-Akt inhibitor. The PI3K/Akt/mTOR pathway regulates cell
growth and survival. A phase III clinical trial is evaluating ipatasertib for the treatment of first line
castration-resistant prostate cancer.
- Managed By:
-
1. Roche Group
- Partner:
- Array BioPharma
1. Oncology
RG7446 atezolizumab
Tecentriq
adjuvant renal cell carcinoma
2022
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab,
anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1
(programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III clinical trial is
evaluating Tecentriq for the treatment of adjuvant renal cell carcinoma.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
adjuvant hepatocellular carcinoma in combination with Avastin
2023
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1,
RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death
ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in
combination with Avastin in adjuvant Hepatocellular carcinoma (HCC)
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
Non-small cell lung cancer subcutaneous formulation
2023
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Atezolizumab (anti-PDL1, RG7446,
MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1)
aiming to prevent cancer immune evasion.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
2L non small cell lung cancer (NSCLC) treatment in combination with cabozantinib
2023
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446,
atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand
1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with
cabozantinib for the treatment of 2L non small cell lung cancer (NSCLC)
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
Advanced renal cell carcinoma after immune checkpoint inhibitor treatment in
combination with cabozantinib
2023
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446,
atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand
1) aiming to prevent cancer immune evasion. A phase III trial is evaluating Tecentriq in combination with
cabozantinib for the treatment of advanced renal cell carcinoma after immune checkpoint inhibitor
treatment
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
first line metastatic urothelial carcinoma
2022
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab,
anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1
(programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating
Tecentriq in combination with chemotherapy or as monotherapy in patients with locally advanced or
metastatic urothelial carcinoma who have not received prior systemic therapy.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
maintenance 1L extensive stage-small cell lung cancer
2025+
Description/Summary:
Tecentriq plus lurbinectedin in the treatment of 1L extensive stage-small cell lung cancer in the
maintenance setting
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
adjuvant triple-negative breast cancer in combination with paclitaxel
2025+
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446,
Atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand
1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase III clinical trial as
a potential adjuvant treatment, in combination with paclitaxel, for triple-negative breast cancer.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
first line metastatic triple-negative breast cancer in combination with
capecitabine or carboplatin/gemcitabine
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446,
atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand
1) aiming to prevent cancer immune evasion. Tecentriq is being evaluated in a phase III clinical trial as
a potential first-line treatment, in combination with capecitabine or carboplatin/gemcitabine, for
metastatic triple-negative breast cancer.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
adjuvant squamous cell carcinoma of the head and neck
2024
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq, (atezolizumab,
anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1
(programmed death ligand 1) aiming to prevent cancer immune evasion. A phase III trial is evaluating
Tecentriq in patients with adjuvant squamous cell carcinoma of the head and neck (SCCHN).
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446-42 atezolizumab
Tecentriq
ctDNA+ high risk muscle-invasive bladder cancer
2024
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446,
atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand
1) aiming to prevent cancer immune evasion.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7601 venetoclax
Venclexta/Venclyxto
relapsed or refractory t(11;14)-positive multiple myeloma
2023
Description/Summary:
Venclexta (venetoclax, RG7601, GDC-0199, ABT-199) is a novel small molecule Bcl-2 selective inhibitor
designed to restore apoptosis, also known as programmed cell death, by blocking the function of a
pro-survival Bcl-2 family protein. The Bcl-2 family proteins, which are expressed at high levels in many
tumors, play a central role in regulating apoptosis and, consequently, are thought to impact tumor
formation, tumor growth and resistance. A phase III clinical trial is evaluating Venclexta for the
treatment of relapsed or refractory t(11;14)-positive multiple myeloma.
- Managed By:
-
1. Roche Group
- Partner:
- AbbVie, Walter and Eliza Hall Institute
1. Oncology
RG7601 venetoclax
Venclexta/Venclyxto
Newly diagnosed higher-risk myelodysplastic syndrome
2024
Description/Summary:
Venclexta (venetoclax, RG7601) is a novel small molecule Bcl-2 selective inhibitor designed to restore
apoptosis, also known as programmed cell death, by blocking the function of a pro-survival Bcl-2 family
protein. The Bcl-2 family proteins, which are expressed at high levels in many tumors, play a central role
in regulating apoptosis and, consequently, are thought to impact tumor formation, tumor growth, and
resistance.
- Managed By:
-
1. Roche Group
- Partner:
- AbbVie, Walter and Eliza Hall Institute
1. Oncology
RG7828 mosunetuzumab
2L+ Follicular Lymphoma
2025+
Description/Summary:
mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody
designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to
redirect T cells to attack cancer cells.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7853 alectinib
Alecensa
adjuvant ALK-positive non-small cell lung cancer
2022
Description/Summary:
Alecensa (Alectinib, RG7853) is a small molecule designed to selectively target ALK (anaplastic lymphoma
kinase) and to penetrate and stay in the central nervous system. Alectinib binds ALK, inhibiting
downstream malignant pathways that contribute to tumorigenesis and disease progression. A phase III
clinical trial is evaluating Alecensa for the treatment of adjuvant ALK-positive non-small cell lung
cancer.
- Managed By:
-
1. Roche Group
- Partner:
- Chugai
1. Oncology
RG6026 Glofitamab
3L+ Diffuse Large B-Cell Lymphoma
2022
Description/Summary:
Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to
engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody
activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as
non-Hodgkin’s lymphoma.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7446 atezolizumab
Tecentriq
neoadjuvant triple-negative breast cancer
Description/Summary:
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1,
RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death
ligand 1) aiming to prevent cancer immune evasion. A phase III clinical trial is investigating Tecentriq
in combination with nab-paclitaxel (Abraxane) as a potential neoadjuvant (before surgery) treatment for
triple-negative breast cancer.
- Managed By:
-
1. Roche Group
- Roche Only
1. Oncology
RG7596 polatuzumab vedotin
Polivy
first line diffuse large B-cell lymphoma
2021
Description/Summary:
Polivy (Polatuzumab vedotin) is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody
anti-CD79b, conjugated to a potent anti-cancer agent that is selectively delivered to tumor cells. A phase
III clinical trial is evaluating Polivy for the treatment of first line diffuse large B-cell lymphoma.
- Managed By:
-
1. Roche Group
- Partner:
- Seattle Genetics
1. Oncology
RG7828 mosunetuzumab
3L+ Follicular Lymphoma
2021
Description/Summary:
mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody
designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to
redirect T cells to attack cancer cells.
- Managed By:
-
1. Roche Group
- Roche Only
2. Immunology
RG6107 crovalimab
paroxysmal nocturnal hemoglobinuria
Description/Summary:
Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using
recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit
complement activation, which is the cause of a number of diseases. As the complement system is a key
innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of
complement-mediated diseases. A phase I/II clinical trial is evaluating crovalimab for the treatment of
paroxysmal nocturnal hemoglobinuria.
- Managed By:
-
1. Roche Group
- Partner:
- Chugai
2. Immunology
RG6287
Inflammatory bowel disease
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
2. Immunology
RG6314
asthma
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
2. Immunology
RG6315
Systemic Sclerosis
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
2. Immunology
RG6418 selnoflast (NLRP3
inhibitor)
Inflammation
Description/Summary:
NLRP3 inhibitor
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
2. Immunology
RG7828 mosunetuzumab
Systemic lupus erythematosus
Description/Summary:
mosunetuzumab (Anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody
designed to target both CD20 on B cells and CD3 on T cells.
- Managed By:
-
1. Roche Group
- Roche Only
2. Immunology
RG7880 efmarodocokin alfa
Acute graft-versus-host disease
Description/Summary:
efmarodocokin alfa (IL22-Fc, UTTR1147A) is a recombinant human protein with potential application across
multiple inflammatory and metabolic diseases.
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
2. Immunology
IONIS ASO factor B
IgA-nephropathy
Description/Summary:
ASO factor B (IONIS) is an antisense oligonucleotide that inhibits complement factor B gene expression by
binding with factor B mRNA. ASO factor B is being studied for the treatment of IgA-nephropathy. A phase II
clinical trial is evaluating ASO factor B for the treatment of IgA-nephropathy.
- Managed By:
-
0. -
- Partner:
- Ionis
2. Immunology
RG6149 astegolimab
chronic obstructive disease
Description/Summary:
astegolimab (RG6149, anti-ST2, AMG 282) is a fully human monoclonal antibody designed to inhibit binding
of interleukin-33 (IL-33) to the ST2 receptor. A phase II clinical trial is evaluating RG6149 for the
treatment of chronic obstructive disease
- Managed By:
-
4. Genentech Research and Early Development
- Partner:
- Amgen
2. Immunology
RG6173
asthma
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
2. Immunology
RG6354 zinpentraxin alfa
myelofibrosis
2025+
Description/Summary:
Phase II study of zinpentraxin alfa (pentraxin-2 (rhPTX-2; PRM-151) in myelofibrosis
- Managed By:
-
1. Roche Group
- Roche Only
2. Immunology
RG3648 omalizumab
Xolair
Food allergy
2023
Description/Summary:
Xolair (omalizumab, RG3648) is a monoclonal antibody that specifically targets the antibody IgE
(immunoglobulin E). In nasal polyps (NP) IgE is increased in mucosal tissue and frequently in serum.
- Managed By:
-
1. Roche Group
- Partner:
- Novartis
2. Immunology
RG6107 crovalimab
Paroxysmal Nocturnal Hemoglobinuria (PNH) C5 inhibitor naive patients
2022
Description/Summary:
Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using
recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit
complement activation, which is the cause of a number of diseases. As the complement system is a key
innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of
complement-mediated diseases.
- Managed By:
-
1. Roche Group
- Partner:
- Chugai
2. Immunology
RG6107 crovalimab
Paroxysmal Nocturnal Hemoglobinuria (PNH) patients switching from a C5 inhibitor
Description/Summary:
Crovalimab (RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using
recycling antibody technology. By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit
complement activation, which is the cause of a number of diseases. As the complement system is a key
innate immune defense mechanism, we plan to study the potential of this antibody in a broader range of
complement-mediated diseases.
- Managed By:
-
1. Roche Group
- Partner:
- Chugai
2. Immunology
RG6354 zinpentraxin alfa
Idiopathic pulmonary fibrosis
2024
Description/Summary:
Phase II study of zinpentraxin alfa (pentraxin-2 (rhPTX-2; PRM-151) in idiopathic pulmonary fibrosis
- Managed By:
-
1. Roche Group
- Roche Only
2. Immunology
RG7159 obinutuzumab
Gazyva/Gazyvaro
Systemic Lupus Erythematosus
2025+
Description/Summary:
Obinutuzumab (RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal
antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and
was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity
to the cell surface in a type II configuration.
- Managed By:
-
1. Roche Group
- Partner:
- Biogen Idec
2. Immunology
RG7159 obinutuzumab
Gazyva/Gazyvaro
lupus nephritis
2024
Description/Summary:
Obinutuzumab (RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal
antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and
was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity
to the cell surface in a type II configuration.
- Managed By:
-
1. Roche Group
- Partner:
- Biogen Idec
2. Immunology
RG7159-7 obinutuzumab
Gazyva/Gazyvaro
membranous Nephropathy
2025+
Description/Summary:
Obinutuzumab (RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal
antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and
was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity
to the cell surface in a type II configuration.
- Managed By:
-
1. Roche Group
- Partner:
- Biogen Idec
3. Ophthalmology
RG6120 VEGF-Ang2 DutaFab
neovascular age-related macular degeneration
Description/Summary:
RG6120 (VEGF-Ang2 DutaFab) is a bispecific Fab molecule targeting vascular endothelial growth factor
(VEGF) and Angiopoietin 2 (Ang-2). Built on the DutaFab platform, RG6120 is specifically designed to be
compatible with the Port Delivery System.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
3. Ophthalmology
RG6312
geographic atrophy
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
3. Ophthalmology
RG6501 OpRegen
geographic atrophy
Description/Summary:
OpRegen is a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders under
development by Lineage Cell Therapeutics in collaboration with Roche
- Managed By:
-
0. -
- Partner:
- Lineage Cell Therapeutics
3. Ophthalmology
RG7921
neovascular age related macular degeneration
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
3. Ophthalmology
IONIS ASO factor B
geographic atrophy
Description/Summary:
ASO factor B (IONIS) is an antisense oligonucleotide that inhibits complement factor B gene expression by
binding with factor B mRNA. ASO factor B is being studied for the treatment of geographic atrophy. A phase
II clinical trial is evaluating ASO factor B for the treatment of geographic atrophy.
- Managed By:
-
0. -
- Partner:
- Ionis
3. Ophthalmology
RG6147 galegenimab (HtrA1)
geographic atrophy
Description/Summary:
galegenimab (HtrA1)
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
3. Ophthalmology
RG6179
diabetic macular edema
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
3. Ophthalmology
RG7774
retinal disease
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
3. Ophthalmology
RG6321 Port Delivery System with
ranibizumab
Susvimo
diabetic macular edema
2023
Description/Summary:
Ranibizumab (RG6321), the active ingredient of Lucentis, is a monoclonal antibody fragment. It is
designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to
play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability
(leakiness) of the vessels. A phase III clinical trial is evaluating ranibizumab delivered via the port
delivery system implant for the treatment of patients with diabetic macular edema (DME).
- Managed By:
-
1. Roche Group
- Partner:
- ForSight VISION4
3. Ophthalmology
RG6321 Port Delivery System with
ranibizumab
Susvimo
diabetic retinopathy without center-involved diabetic macular edema
2023
Description/Summary:
Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind
to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical
role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the
vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery
system implant for the treatment of patients with subfoveal neovascular age-related macular degeneration.
The primary outcome measure of the trial is the time until a patient first requires a refill of the
implant.
- Managed By:
-
1. Roche Group
- Partner:
- ForSight VISION4
3. Ophthalmology
RG6321-3 Port Delivery System with
ranibizumab
Susvimo
age-related macular -36 week refill interval
2025+
Description/Summary:
Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind
to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical
role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the
vessels. A phase III clinical trial is evaluating ranibizumab delivered via the ranibizumab port delivery
system implant refilled every 36 weeks for the treatment of patients with subfoveal neovascular
age-related macular degeneration. The primary outcome measure of the trial is the time until a patient
first requires a refill of the implant.
- Managed By:
-
1. Roche Group
- Partner:
- ForSight VISION4
3. Ophthalmology
RG7716 faricimab
Vabysmo
Macular edema secondary to central retinal vein occlusion
2023
Description/Summary:
Faricimab (RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on
one arm and angiopoietin (Ang)-2 on the other arm.
- Managed By:
-
1. Roche Group
- Roche Only
3. Ophthalmology
RG7716 faricimab
Vabysmo
Macular edema secondary to branch retinal vein occlusion
2023
Description/Summary:
Faricimab (RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on
one arm and angiopoietin (Ang)-2 on the other arm.
- Managed By:
-
1. Roche Group
- Roche Only
4. Infectious Diseases
RG6006 Abx MCP
Acinetobacter baumannii infections
Description/Summary:
RG6006 (Abx MCP) is a small molecule, novel chemical class antibiotic for the treatment of Acinetobacter
baumannii infections.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
4. Infectious Diseases
RG6319 LepB inhibitor
complicated urinary track infection
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
4. Infectious Diseases
RG7854
chronic hepatitis B infection
Description/Summary:
TLR7 agonist (RG7854) is an oral, small molecule immuno-modulator activating the TLR (toll-like receptor)
7 and to a weaker extent TLR8. It is developed as best-in-disease for finite chronic hepatitis B
combination therapy. A phase I clinical trial is evaluating RG7854 for the treatment of chronic hepatitis
B infection.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
4. Infectious Diseases
RG7907
chronic hepatitis B infection
Description/Summary:
CpAM (RG7907) is an orally administered small molecule, class I hepatitis B virus (HBV) core protein
allosteric modulator, that disrupts HBV nucleocapsids assembly and induces the depletion of functional
core proteins, thereby effectively inhibiting HBV replication.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
4. Infectious Diseases
RG6084 PD-L1 LNA
chronic hepatitis B infection
Description/Summary:
RG6084 (PD-L1 LNA) is a liver-directed locked nucleic acid oligonucleotide targeting the PD-L1/PD-1
immune checkpoint inhibitory pathway, which is overexpressed in the liver of patients with chronic
hepatitis B.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
4. Infectious Diseases
RG6346 HBV siRNA
Hepatitis B virus
Description/Summary:
RG6346 (DCR-HBVS) is a liver-targeted siRNA that employs RNA interference (RNAi) for selective knock-down
of Hepatitis B virus gene expression in infected hepatocytes, inhibiting the production of viral factors
required for viral replication. RG6346 leverages Dicerna Pharmaceuticals, Inc.’s proprietary GalXC™ RNAi
technology.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
4. Infectious Diseases
RG7854
chronic hepatitis B infection
Description/Summary:
TLR7 agonist (RG7854) being studied in the Roche Hepatitis B PIRANGA combination platform
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
4. Infectious Diseases
RG6152 baloxavir marboxil
Xofluza
influenza, pediatric patients (0-1yr)
2022
Description/Summary:
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and
potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a
phase III clinical trial for the treatment of pediatric patients with the flu.
- Managed By:
-
1. Roche Group
- Partner:
- Shionogi
4. Infectious Diseases
RG6152 baloxavir marboxil
Xofluza
influenza, direct transmission
2023
Description/Summary:
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and
potent antiviral activity against seasonal influenza A and B viruses.
- Managed By:
-
1. Roche Group
- Partner:
- Shionogi
4. Infectious Diseases
RG6152 baloxavir marboxil
Xofluza
influenza, pediatric patients (1-12yr)
2021
Description/Summary:
Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and
potent antiviral activity against seasonal influenza A and B viruses. Xofluza is being evaluated in a
phase III clinical trial for the treatment of pediatric patients with the flu.
- Managed By:
-
1. Roche Group
- Partner:
- Shionogi
4. Infectious Diseases
RG6412 imdevimab
REGEN-COV-2
hospitalised adult patients with COVID-19
Description/Summary:
- Managed By:
-
0. -
- Partner:
- Regeneron
4. Infectious Diseases
RG6413 casirivimab
REGEN-COV-2
hospitalized patients with COVID-19
2021
Description/Summary:
- Managed By:
-
0. -
- Partner:
- Regeneron
5. CardioMetabolism
RG6338
metabolic diseases
Description/Summary:
- Managed By:
-
4. Genentech Research and Early Development
- Roche Only
5. CardioMetabolism
RG6359 SPK-3006
Pompe disease
Description/Summary:
- Managed By:
-
1. Roche Group
- Roche Only
6. Neuroscience
RG6035 BS-CD20
multiple sclerosis
Description/Summary:
Brain shuttle technology to transferAnti-CD20 antibody across the blood brain barrier and increase
antibody concentrations in the brain/CNS
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG6091 rugonersen
Angelman syndrome
Description/Summary:
rugonersen (UBE3-LNA) is a locked nucleic acid developed for the treatment of Angelman syndrome which is
caused by a lack of UBE3A expression in the brain. The LNA targets the paternal antisense RNA and enables
the expression of UB3A in neurons.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG6163 NME
psychiatric disorders
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG6182
neurodegenerative diseases
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG6237
neuromuscular disorders
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG6289
Alzheimer's disease
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG7637
neurodevelopmental disorders
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG6100 semorinemab
Alzheimer's disease
2025+
Description/Summary:
RG6100 (Anti Tau) is an investigational medicine being evaluated as a potential treatment for Alzheimer’s
disease. A phase II clinical trial is evaluating RG6100 for the treatment of patients with Alzheimer's
disease.
- Managed By:
-
4. Genentech Research and Early Development
- Partner:
- AC Immune
6. Neuroscience
RG6102 Brain shuttle
gantenerumab
Alzheimer's
2025+
Description/Summary:
Brain shuttle technology to transfer gantenerumab across the blood brain barrier and increase antibody
concentrations in the brain
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG7412 crenezumab
Alzheimer's disease
2025+
Description/Summary:
Crenezumab (RG7412) is a humanized monoclonal antibody, which binds to amyloid beta (Abeta). Abeta is the
main constituent of amyloid plaque in the brains of patients with Alzheimer's disease and is proposed to
be causative in the development of the disease. A phase II clinical trial is evaluating crenezumab in
healthy individuals with a history of familial Alzheimer’s disease.
- Managed By:
-
1. Roche Group
- Partner:
- AC Immune
6. Neuroscience
RG7816 alogabat (GABA-Aa5 PAM)
autism spectrum disorder
2025+
Description/Summary:
alogabat (GABA-Aa5 PAM) is a small molecule highly selective positive allosteric modulator of the GABAA
α5 receptor, which is expressed in key brain regions for autism spectrum disorder. Two phase I clinical
trial is evaluating RG7816 for the treatment of patients with autism spectrum disorder.
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG7906 ralmitaront
psychiatric disorders
Description/Summary:
- Managed By:
-
2. Pharma Research and Early Development
- Roche Only
6. Neuroscience
RG7935 prasinezumab
Parkinson's disease
2025+
Description/Summary:
Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and
be involved in the pathogenesis of Parkinson's disease. It has been tested in preclinical models of
synuclein-related disease and has shown a reduction of neurodegeneration. A phase II clinical trial is
evaluating prasinezumab for the treatment of patients with Parkinson's disease.
- Managed By:
-
2. Pharma Research and Early Development
- Partner:
- Prothena
6. Neuroscience
RG1450 gantenerumab
Alzheimer's disease
2022
Description/Summary:
Gantenerumab (RG1450) is a fully human monoclonal antibody that binds and neutralises disease-relevant
aggregated forms of amyloid-beta: those that accumulate as plaques in the brain and those which interfere
with brain-cell functioning. A phase III clinical trial is evaluating gantenerumab for the treatment of
Alzheimer's disease.
- Managed By:
-
1. Roche Group
- Partner:
- Morphosys
6. Neuroscience
RG6042 tominersen
Huntington's Disease
Description/Summary:
tominersen (ASO-HTT, RG6042) is an antisense drug in development for the treatment of Huntington's
Disease. tominersen is designed to reduce the production of all forms of the huntingtin (HTT) protein,
which in its mutated variant (mHTT) is responsible for Huntington's Disease. Multiple clinical trials are
evaluating tominersen for the treatment of patients with Huntington's Disease.
- Managed By:
-
1. Roche Group
- Partner:
- Ionis
6. Neuroscience
RG6168 satralizumab
Enspryng
Myasthenia Gravis
2025+
Description/Summary:
Satralizumab (RG6168) is a humanized monoclonal antibody to the interleukin-6 receptor. A phase III
clinical trial is evaluating satralizumab for the treatment of patients with Myasthenia Gravis
- Managed By:
-
1. Roche Group
- Partner:
- Chugai
6. Neuroscience
RG6356 delandistrogene moxeparvovec
(SRP-9001)
Duchenne muscular dystrophy
2024
Description/Summary:
Phase III gene therapy in Duchenne muscular dystrophy (DMD)
- Managed By:
-
1. Roche Group
- Roche Only
6. Neuroscience
RG7845 fenebrutinib
Primary progressive multiple sclerosis (PPMS)
2025+
Description/Summary:
RG7845 (GDC-0853) is a novel Bruton’s tyrosine kinase (BTK) inhibitor that helps block B cell
proliferation. RG7845 binds to BTK in a novel way that is believed to increase its effectiveness.
- Managed By:
-
1. Roche Group
- Roche Only
6. Neuroscience
RG7845 fenebrutinib
Relapsing multiple sclerosis (RMS)
2025+
Description/Summary:
RG7845 (GDC-0853) is a novel Bruton’s tyrosine kinase (BTK) inhibitor that helps block B cell
proliferation. RG7845 binds to BTK in a novel way that is believed to increase its effectiveness.
- Managed By:
-
1. Roche Group
- Roche Only
6. Neuroscience
RG7916 risdiplam
Evrysdi
spinal muscular atrophy pediatric <2 months
2021
Description/Summary:
Risdiplam (RG7916) is an investigational oral SMN2 splicing modifier being studied in the treatment
of spinal muscular atrophy. Multiple phase II and phase II/III are evaluating risdiplan for the
treatment of patients with spinal muscular atrophy.
- Managed By:
-
1. Roche Group
- Partner:
- PTC Therapeutics, SMA Foundation
7. Other
CHU
endometriosis
Description/Summary:
- Managed By:
-
3. Chugai
- Partner:
- Chugai
7. Other
CHU anti-FIXa/FX
hemophilia A
Description/Summary:
NXT007 is an optimized anti-FIXa/FX bispecific monoclonal antibody. NXT007 has an enhanced hemostatic
activity and improved pharmacokinetics by antibody engineering technologies. The bispecific antibody is
in phase I/II clinical study for healthy volunteers and hemophilia A.
- Managed By:
-
3. Chugai
- Roche Only
7. Other
RG6357 SPK-8011
hemophilia A
Description/Summary:
- Managed By:
-
0. -
- Roche Only
7. Other
RG6358 SPK-8016
hemophilia A with inhibitors to factor VIII
Description/Summary:
- Managed By:
-
0. -
- Roche Only
7. Other
RG6013 emicizumab
Mild to moderate hemophilia A, patients without FVIII inhibitors
2021
Description/Summary:
Emicizumab (RG6013, ACE910) is a bispecific antibody that mimics coagulation factor VIII, an essential
blood clotting protein. It is being investigated as a therapy for people with mild ot moderate
hemophilia A, a congenital bleeding disorder that is caused by deficiency or dysfunction of coagulation
factor VIII.
- Managed By:
-
1. Roche Group
- Partner:
- Chugai